Search clinical trials for: human rabies immunoglobulins

Total 24571 results

Genrix (Shanghai) Biopharmaceutical Co., Ltd.

Recruiting

Study to Evaluate GR1801's Efficacy and Safety

Rabies Post-exposure Prophylaxis

China
Changchun BCHT Biotechnology Co.
The First Affiliated Hospital of Yunnan University of Traditional Chinese... and other collaborators

Not yet recruiting

Safety, Pharmacokinetics, and Pharmacodynamic Testing of Rabies mAb CBB 1

Rabies Virus Infection

China
The Methodist Hospital Research Institute
Grifols Biologicals, LLC

Recruiting

Survey of Human Rabies Immune Globulin Safety in Children

Rabies | Rabies Human | Pediatrics | Rabies Virus Infection

United States
Sanofi Pasteur, a Sanofi Company

Completed

Study of Purified Vero Rabies Vaccine Compared With a Reference Rabies Vaccine as Simulated Rabies Post-Exposure Prophylaxis in Adults in Thaïland

Rabies (Healthy Volunteers)

Thailand
Sanofi Pasteur, a Sanofi Company

Completed

Study of Purified Vero Rabies Vaccine Compared With a Reference Rabies Vaccine as Simulated Rabies Post-Exposure Prophylaxis in Adult and Pediatric Population in Thaïland

Rabies (Healthy Volunteers)

Thailand
Synermore Biologics (Suzhou) Co., Ltd.
Simoon Record Pharma Information Consulting Co., Ltd.

Completed

A Phase III Clinical Study to Evaluate SYN023's Efficacy and Safety

RNA Virus Infections | Virus Diseases | Mononegavirales Infections | Rabies | Rhabdoviridae Infections | Communicable Disease

China
Sanofi Pasteur, a Sanofi Company

Completed

Study of Purified Vero Rabies Vaccine Compared With Two Reference Rabies Vaccines in a Simulated Post-Exposure Regimen in Adults

Rabies (Healthy Volunteers)

France
Sanofi Pasteur, a Sanofi Company

Completed

Immunogenicity and Safety of a Purified Vero Rabies Vaccine

Rabies Virus

United States
Synermore Biologics Co., Ltd.
inVentiv Health Clinical

Completed

A Comparison of the Safety, PD and PK of a Single Dose of SYN023 Administered With Licensed Rabies Vaccines (RabiesMab)

Human Rabies

United States
Queen Saovabha Memorial Institute

Completed

Human Rabies Immunoglobulin (HRIG)- Dosage Determination and Interference With the Active Immune Response

Rabies

Thailand
Novartis
Novartis Vaccines

Completed

Safety and Immunogenicity of Two Intradermal Rabies Vaccine Regimens Administered With and Without Human Rabies Immunoglobulin in Subjects ≥ 1 Years of Age

Rabies Infection

Philippines, Thailand
Grifols Therapeutics LLC

Completed

An Open-label, Single-Arm Study to Evaluate the Safety and Rabies Virus Antibody Titers of Intramuscularly Administered Rabies Immune Globulin (Human)

Rabies

United States
Crucell Holland BV

Completed

Rabies Virus Neutralizing Activity and Safety of CL184, a Monoclonal Antibody Cocktail, in Simulated Rabies Post-Exposure Prophylaxis in Healthy Adults

Rabies

India
National Cancer Institute (NCI)

Not yet recruiting

Testing the Addition of ASTX660 (Tolinapant) to the Usual Chemotherapy Treatment (Paclitaxel With or Without Bevacizumab) in Patients With Recurrent Ovarian Cancer

Recurrent Ovarian High Grade Serous Adenocarcinoma | Recurrent Platinum-Resistant Ovarian Carcinoma | Recurrent Fallopian Tube Clear Cell Adenocarcinoma | Recurrent Fallopian Tube Undifferentiated Carcinoma | Recurrent Ovarian Clear Cell Adenocarcinoma | Recurrent Ovarian Undifferentiated Carcinoma and other conditions
Dana-Farber Cancer Institute
Eli Lilly and Company

Not yet recruiting

ALPINE: Maintenance Letrozole/Abemaciclib vs Pembrolizumab

Endometrial Cancer | Recurrent Endometrial Cancer | TP53

United States
Changchun BCHT Biotechnology Co.
The First Affiliated Hospital of Yunnan University of Traditional Chinese... and other collaborators

Not yet recruiting

Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of the Fully Human Anti-tetanus Toxin Monoclonal Antibody A82 / B86 Injection Combination Formulation

Clostridium Tetanus
National Cancer Institute (NCI)

Not yet recruiting

Comparing Rituximab and Mosunetuzumab Drug Treatments for People With Low Tumor Burden Follicular Lymphoma

Classic Follicular Lymphoma | Follicular Lymphoma With Unusual Cytological Features
National Cancer Institute (NCI)

Not yet recruiting

Anti-Lag-3 (Relatlinib) and Anti-PD-1 Blockade (Nivolumab) Versus Standard of Care (Lomustine) for the Treatment of Patients With Recurrent Glioblastoma

Recurrent Glioblastoma
National Cancer Institute (NCI)

Not yet recruiting

Testing the Combination of an Anti-cancer Drug, Iadademstat, With Other Anti-cancer Drugs (Atezolizumab or Durvalumab) at Improving Outcomes for Small Cell Lung Cancer

Stage IV Lung Cancer AJCC v8 | Extensive Stage Lung Small Cell Carcinoma
Sunshine Guojian Pharmaceutical (Shanghai) Co.,...

Recruiting

A Study of SSGJ-613 in Gout Subjects Initiating Urate-Lowering Treatment.

Gout Arthritis

China
Yuanquan Yang
Gateway for Cancer Research

Not yet recruiting

Futibatinib in Combination With Durvalumab Prior to Cystectomy for the Treatment of Muscle-Invasive Bladder Cancer Patients Who Are Ineligible for Cisplatin-based Therapy

Bladder Urothelial Carcinoma | Stage IIIA Bladder Cancer AJCC v8 | Muscle Invasive Bladder Carcinoma | Stage II Bladder Cancer AJCC v8

United States
National Cancer Institute (NCI)

Not yet recruiting

Adding Nivolumab to Usual Treatment for People With Advanced Stomach or Esophageal Cancer, The PARAMMUNE Trial

Clinical Stage III Gastric Cancer AJCC v8 | Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8 | Clinical Stage IV Gastric Cancer AJCC v8 | Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8 | Metastatic Gastric Adenocarcinoma | Metastatic Gastroesophageal Junction... and other conditions
Academic and Community Cancer Research United
National Cancer Institute (NCI)

Not yet recruiting

Retifanlimab With Bevacizumab and Hypofractionated Radiotherapy for the Treatment of Recurrent Glioblastoma

Recurrent Glioblastoma | Recurrent WHO Grade 4 Glioma

United States
Bio-Thera Solutions

Recruiting

Assessment of Safety, Tolerability and Pharmacokinetics With BAT4706 and BAT1308 in Advanced Solid Tumors Patients

Advanced Solid Tumor

China
Takeda
Takeda Development Center Americas, Inc.

Not yet recruiting

A Study About the Long-Term Safety of TAK-881 in People With Primary Immunodeficiency Diseases

Primary Immunodeficiency Diseases (PID)
Mayo Clinic
National Cancer Institute (NCI)

Not yet recruiting

Radioembolization With Tremelimumab and Durvalumab for Locally Advanced Unresectable or Oligo-Metastatic Intrahepatic Cholangiocarcinoma

Stage III Intrahepatic Cholangiocarcinoma AJCC v8 | Stage IV Intrahepatic Cholangiocarcinoma AJCC v8 | Unresectable Intrahepatic Cholangiocarcinoma | Locally Advanced Intrahepatic Cholangiocarcinoma | Oligometastatic Intrahepatic Cholangiocarcinoma

United States
National Cancer Institute (NCI)

Recruiting

Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer

Anatomic Stage II Breast Cancer AJCC v8 | Anatomic Stage III Breast Cancer AJCC v8 | Hormone Receptor-Positive Breast Carcinoma | HER2-Negative Breast Carcinoma

United States
National Cancer Institute (NCI)

Recruiting

Durvalumab With Gemcitabine and Cisplatin for the Treatment of High Risk Resectable Liver Cancer Before Surgery

Intrahepatic Cholangiocarcinoma

United States
First Affiliated Hospital of Wenzhou Medical University

Recruiting

Early and Late Prognosis in Patients With Guillain-Barre Syndrome

Guillain-Barre Syndrome

China
SWOG Cancer Research Network
National Cancer Institute (NCI)

Not yet recruiting

Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)

Stage IV Lung Cancer AJCC v8 | Recurrent Lung Non-Small Cell Carcinoma
National Cancer Institute (NCI)

Recruiting

Testing the Addition of BMS-986016 (Relatlimab) to the Usual Immunotherapy After Initial Treatment for Recurrent or Metastatic Nasopharyngeal Cancer

Recurrent Nasopharyngeal Carcinoma | Stage IV Nasopharyngeal Carcinoma AJCC v8 | Metastatic Nasopharyngeal Carcinoma

United States, China
Assistance Publique - Hôpitaux de Paris

Not yet recruiting

Good Use of Normal Human ImmunoGlobulins (NHIg): Feasibility of Integrating the Criteria of Hierarchy During of NHIg Dispensations (BUS-IG)

Immunoglobulins
Margaret Gatti-Mays

Recruiting

Gemcitabine and Ex Vivo Expanded Allogenic Universal Donor, TGFβi Natural Killer (NK) Cells With or Without Naxitamab (Danyelza) for the Treatment of Patients With Metastatic, GD2 Expressing, HER2 Negative Breast Cancer

Anatomic Stage IV Breast Cancer AJCC v8 | HER2-Negative Breast Carcinoma

United States
Peking Union Medical College Hospital

Not yet recruiting

CsA+ATG+AVA vs. CsA+AVA for the Treatment of Newly-diagnosed SAA in the Elderly

Aplastic Anemia

China
City of Hope Medical Center
National Cancer Institute (NCI)

Recruiting

Allogeneic CD6 Chimeric Antigen Receptor T Regulatory Cells (CD6-CAR Tregs) for the Treatment of Patients With Chronic Graft Versus Host Disease After Allogeneic Hematopoietic Cell Transplantation

Chronic Graft Versus Host Disease | Hematologic and Lymphocytic Disorder | Steroid Refractory Graft Versus Host Disease

United States
National Cancer Institute (NCI)

Recruiting

Testing the Role of DNA Released From Tumor Cells Into the Blood in Guiding the Use of Immunotherapy After Surgical Removal of the Bladder for Bladder Cancer Treatment, MODERN Study

Stage III Bladder Urothelial Carcinoma AJCC v6 and v7 | Stage IV Bladder Urothelial Carcinoma AJCC v7 | Stage II Bladder Urothelial Carcinoma AJCC v6 and v7 | Muscle Invasive Bladder Urothelial Carcinoma

United States
Ningbo Rongan Biological Pharmaceutical Co., Ltd.

Not yet recruiting

Clinical Trial of Freeze-dried Human Rabies Vaccine (Without Serum Vero Cells)

Rabies

China
University of Washington
Janssen Scientific Affairs, LLC

Recruiting

Golimumab and Apalutamide for the Treatment of Castration-Resistant Prostate Cancer, TRAMP Study

Castration-Resistant Prostate Carcinoma | Prostate Adenocarcinoma

United States
Fred Hutchinson Cancer Center
National Cancer Institute (NCI); Takeda

Recruiting

IVIG for Infection Prevention After CAR-T-Cell Therapy

Lymphoma

United States
OHSU Knight Cancer Institute
Oregon Health and Science University; Incyte Corporation

Recruiting

Tafasitamab, Acalabrutinib, and Obinutuzumab for the Treatment of Previously Untreated Chronic Lymphocytic Leukemia

Chronic Lymphocytic Leukemia

United States
Thomas Jefferson University

Recruiting

Cemiplimab for the Treatment of Locally Advanced Head and Neck Basal Cell Carcinoma Before Surgery

Locally Advanced Basal Cell Carcinoma

United States
Academic and Community Cancer Research United
National Cancer Institute (NCI)

Recruiting

Tafasitamab, Lenalidomide and Venetoclax for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma (V-MIND)

Recurrent Mantle Cell Lymphoma | Refractory Mantle Cell Lymphoma

United States
SWOG Cancer Research Network
National Cancer Institute (NCI); Incyte Corporation; Ipsen; BeiGene

Recruiting

Study Adding Drugs to Usual Treatment for Large B-Cell Lymphoma That Returned or Did Not Respond to Treatment

Recurrent Diffuse Large B-Cell Lymphoma | Refractory Diffuse Large B-Cell Lymphoma | High Grade B-Cell Lymphoma | Grade 3b Follicular Lymphoma | Transformed Non-Hodgkin Lymphoma | High Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 Rearrangements

United States
National Cancer Institute (NCI)

Recruiting

Comparing the Effectiveness of the Immunotherapy Agents Rituximab or Mosunetuzumab in Patients With Nodular Lymphocyte-Predominant Hodgkin Lymphoma

Nodular Lymphocyte Predominant B-Cell Lymphoma | Recurrent Nodular Lymphocyte Predominant B-Cell Lymphoma | Refractory Nodular Lymphocyte Predominant B-Cell Lymphoma

United States
Casey Cosgrove

Recruiting

Combination Niraparib and Dostarlimab Therapy for Recurrent or Persistent Uterine Serous Carcinoma

Recurrent Endometrial Serous Adenocarcinoma

United States
ECOG-ACRIN Cancer Research Group
National Cancer Institute (NCI)

Recruiting

Testing Pump Chemotherapy in Addition to Standard of Care Chemotherapy Versus Standard of Care Chemotherapy Alone for Patients With Unresectable Colorectal Liver Metastases: The PUMP Trial

Metastatic Malignant Neoplasm in the Liver | Metastatic Colorectal Carcinoma | Stage IV Colorectal Cancer AJCC v8 | Unresectable Colorectal Carcinoma

United States
Kirby Institute

Recruiting

Australian Hepatitis and Risk Survey in Prisons (AusHep)

HIV Infections | Hepatitis B | Hepatitis C

Australia
Academisch Medisch Centrum - Universiteit van Amsterdam...
Princess Beatrix Muscle Foundation

Recruiting

Add-on Intravenous Immunoglobulins in Early Myositis (TIMEISMUSCLE)

Myositis | Dermatomyositis | Polymyositis | Antisynthetase Syndrome | Immune-Mediated Necrotizing Myopathy | Inflammatory Myopathy, Idiopathic

Netherlands
David Bond, MD

Recruiting

Tafasitamab and Lenalidomide Followed by Tafasitamab and ICE as Salvage Therapy for Transplant Eligible Patients With Relapsed/ Refractory Large B-Cell Lymphoma

Recurrent Primary Mediastinal (Thymic) Large B-Cell Lymphoma | Refractory Primary Mediastinal (Thymic) Large B-Cell Lymphoma | Recurrent High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements | Refractory High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements | Recurrent... and other conditions

United States
Shanghai HyaMab Biotech Co.,Ltd.

Recruiting

PE0116 and PE0105 Injection in Treatment of Patients With Advanced Solid Tumor

Locally Advanced/Metastatic Solid Tumors

China

Search clinical trials for: human rabies immunoglobulins

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Romania

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations